Author Correction: NADH oxidase-dependent CD39 expression by CD8+ T cells modulates interferon gamma responses via generation of adenosine (Nature Communications, (2015), 6, 1, (8819), 10.1038/ncomms9819);NADH oxidase-dependent CD39 expression by CD8 + T cells modulates interferon gamma responses via generation of adenosine

Nature Communications

Volumn 6, Issue , 2015, Pages

  Bai, Aiping ^a   Moss, Alan ^a   Rothweiler, Sonja ^a   Serena Longhi, Maria ^a   Wu, Yan ^a   Junger, Wolfgang G ^b   Robson, Simon C ^a  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE; ADENOSINE A2 RECEPTOR; ADENOSINE A2 RECEPTOR AGONIST; ADENOSINE DERIVATIVE; AZATHIOPRINE; CD28 ANTIGEN; CD3 ANTIGEN; CD39 ANTIGEN; CGS 24680; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MERCAPTOPURINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; STEROID; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ADENOSINE RECEPTOR; APYRASE; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN; MULTIENZYME COMPLEX; OXIDOREDUCTASE;

AMINO ACID; CELLS AND CELL COMPONENTS; DIGESTIVE SYSTEM DISORDER; ENZYME ACTIVITY; GAMMA RAY RADIATION; GENE EXPRESSION; IMMUNOASSAY; INHIBITION; OXYGEN;

ADULT; AGED; ARTICLE; CD3+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG TARGETING; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PARACRINE SIGNALING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PURINERGIC SIGNALING; SIGNAL TRANSDUCTION; STEROID THERAPY; CHROMATIN IMMUNOPRECIPITATION; COLON; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; YOUNG ADULT;

ADENOSINE; ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD3; APYRASE; BLOTTING, WESTERN; CD8-POSITIVE T-LYMPHOCYTES; CHROMATIN IMMUNOPRECIPITATION; COLON; CROHN DISEASE; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; INTESTINAL MUCOSA; LEUKOCYTES, MONONUCLEAR; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MULTIENZYME COMPLEXES; NADH, NADPH OXIDOREDUCTASES; NADPH OXIDASE; NF-KAPPA B; REACTIVE OXYGEN SPECIES; RECEPTORS, PURINERGIC P1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, CYTOTOXIC; YOUNG ADULT;

EID: 84946780490     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-020-16314-5     Document Type: Erratum

References (62)

1. Saurer, L. & Mueller, C. T cell-mediated immunoregulation in the gastrointestinal tract. Allergy 64, 505-519 (2009).
2. Suzuki, M., Konya, C., Goronzy, J. J. & Weyand, C. M. Inhibitory CD8+ T cells in autoimmune disease. Hum. Immunol. 69, 781-789 (2008).
3. Brown, S. J. & Mayer, L. The immune response in inflammatory bowel disease. Am. J. Gastroenterol. 102, 2058-2069 (2007).
4. Geremia, A., Biancheri, P., Allan, P., Corazza, G. R. & Di Sabatino, A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun. Rev. 13, 3-10 (2014).
5. Coskun, M., Salem, M., Pedersen, J. & Nielsen, O. H. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol. Res. 76, 1-8 (2013).
6. Perrier, C. & Rutgeerts, P. Cytokine blockade in inflammatory bowel diseases. Immunotherapy 3, 1341-1352 (2011).
7. Ito, R. et al. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin. Exp. Immunol. 146, 330-338 (2006).
8. Hommes, D. W. et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 55, 1131-1137 (2006).
9. Reinisch, W. et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm. Bowel Dis. 16, 233-242 (2010).
10. Nateghi Rostami, M. et al. CD8+ T cells as a source of IFN-gamma production in human cutaneous leishmaniasis. PLoS Negl. Trop. Dis. 4, e845 (2010).
11. Bergstrom, I., Backteman, K., Lundberg, A., Ernerudh, J. & Jonasson, L. Persistent accumulation of interferon-gamma-producing CD8+CD56+ T cells in blood from patients with coronary artery disease. Atherosclerosis 224, 515-520 (2012).
12. Li, K. K. & Adams, D. H. Antitumor CD8+ T cells in hepatocellular carcinoma: present but exhausted. Hepatology 59, 1232-1234 (2014).
13. Funderburg, N. T. et al. Circulating CD4+ and CD8+ T cells are activated in IBD and are associated with plasma markers of inflammation. Immunology 140, 87-97 (2013).
14. Lee, J. C. et al. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J. Clin. Invest. 121, 4170-4179 (2011).
15. Kesarwani, P., Murali, A. K., Al-Khami, A. A. & Mehrotra, S. Redox regulation of T-cell function: from molecular mechanisms to significance in human health and disease. Antioxid. Redox Signal. 18, 1497-1534 (2012).
16. Friedman, D. J. et al. From the Cover: CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc. Natl Acad. Sci. USA 106, 16788-16793 (2009).
17. Deaglio, S. et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204, 1257-1265 (2007).
18. Borsellino, G. et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 110, 1225-1232 (2007).
19. Junger, W. G. Immune cell regulation by autocrine purinergic signalling. Nat. Rev. Immunol. 11, 201-212 (2011).
20. Reutershan, J. et al. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J. 23, 473-482 (2009).
21. Dwyer, K. M. et al. Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am. J. Transplant. 10, 2410-2420 (2010).
22. Bai, A. et al. CD39 and CD161 modulate Th17 responses in Crohn's disease. J. Immunol. 193, 3366-3377 (2014).
23. Dardalhon, V. et al. CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J. Immunol. 175, 1558-1565 (2005).
24. Groom, J. R. & Luster, A. D. CXCR3 in T-cell function. Exp. Cell Res. 317, 620-631 (2011).
25. Lu, B. et al. GADD45gamma mediates the activation of the p38 and JNK MAP kinase pathways and cytokine production in effector TH1 cells. Immunity 14, 583-590 (2001).
26. Sica, A. et al. Interaction of NF-kappaB and NFAT with the interferon-gamma promoter. J. Biol. Chem. 272, 30412-30420 (1997).
27. Bedard, K. & Krause, K. H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 87, 245-313 (2007).
28. Doherty, G. A. et al. CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease. Eur. J. Immunol. 42, 3062-3072 (2012).
29. Linnemann, C. et al. Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling. Immunology 128, e728-e737 (2009).
30. Erdmann, A. A. et al. Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood 105, 4707-4714 (2005).
31. Antonioli, L. et al. Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders. Curr. Drug Targets 13, 842-862 (2012).
32. Rescigno, M. & Di Sabatino, A. Dendritic cells in intestinal homeostasis and disease. J. Clin. Invest. 119, 2441-2450 (2009).
33. Dhiman, M. & Garg, N. J. NADPH oxidase inhibition ameliorates Trypanosoma cruzi-induced myocarditis during Chagas disease. J. Pathol. 225, 583-596 (2011).
34. Beltran, B. et al. Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naive and treated Crohn's disease. Inflamm. Bowel Dis. 16, 76-86 (2010).
35. Fais, S. et al. Interferon expression in Crohn's disease patients: increased interferon-gamma and -alpha mRNA in the intestinal lamina propria mononuclear cells. J. Interferon Res. 14, 235-238 (1994).
36. Mannon, P. J. et al. Suppression of inflammation in ulcerative colitis by interferon-beta-1a is accompanied by inhibition of IL-13 production. Gut 60, 449-455 (2011).
37. Sareila, O., Kelkka, T., Pizzolla, A., Hultqvist, M. & Holmdahl, R. NOX2 complex-derived ROS as immune regulators. Antioxid. Redox Signal. 15, 2197-2208 (2011).
38. Sena, L. A. & Chandel, N. S. Physiological roles of mitochondrial reactive oxygen species. Mol. Cell 48, 158-167 (2012).
39. Van Buul, J. D., Fernandez-Borja, M., Anthony, E. C. & Hordijk, P. L. Expression and localization of NOX2 and NOX4 in primary human endothelial cells. Antioxid. Redox Signal. 7, 308-317 (2005).
40. Anilkumar, N., Weber, R., Zhang, M., Brewer, A. & Shah, A. M. Nox4 and nox2 NADPH oxidases mediate distinct cellular redox signaling responses to agonist stimulation. Arterioscler. Thromb. Vasc. Biol. 28, 1347-1354 (2008).
41. Kaminski, M., Kiessling, M., Suss, D., Krammer, P. H. & Gulow, K. Novel role for mitochondria: protein kinase Ctheta-dependent oxidative signaling organelles in activation-induced T-cell death. Mol. Cell. Biol. 27, 3625-3639 (2007).
42. Sena, L. A. et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity 38, 225-236 (2013).
43. Purushothaman, D. & Sarin, A. Cytokine-dependent regulation of NADPH oxidase activity and the consequences for activated T cell homeostasis. J. Exp. Med. 206, 1515-1523 (2009).
44. Pelletier, M., Lepow, T. S., Billingham, L. K., Murphy, M. P. & Siegel, R. M. New tricks from an old dog: mitochondrial redox signaling in cellular inflammation. Semin. Immunol. 24, 384-392 (2012).
45. Zhi, L., Ustyugova, I. V., Chen, X., Zhang, Q. & Wu, M. X. Enhanced Th17 differentiation and aggravated arthritis in IEX-1-deficient mice by mitochondrial reactive oxygen species-mediated signaling. J. Immunol. 189, 1639-1647 (2012).
46. Lee, K., Won, H. Y., Bae, M. A., Hong, J. H. & Hwang, E. S. Spontaneous and aging-dependent development of arthritis in NADPH oxidase 2 deficiency through altered differentiation of CD11b+ and Th/Treg cells. Proc. Natl Acad. Sci. USA 108, 9548-9553 (2011).
47. Tse, H. M. et al. NADPH oxidase deficiency regulates Th lineage commitment and modulates autoimmunity. J. Immunol. 185, 5247-5258 (2010).
48. Vlahos, R. et al. Inhibition of Nox2 oxidase activity ameliorates influenza A virus-induced lung inflammation. PLoS Pathog. 7, e1001271 (2011).
49. Dwyer, K. M. et al. CD39 and control of cellular immune responses. Purinergic Signal. 3, 171-180 (2007).
50. Cekic, C. & Linden, J. Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment. Cancer Res. 74, 7239-7249 (2014).
51. Himer, L. et al. Adenosine A2A receptor activation protects CD4+ T lymphocytes against activation-induced cell death. FASEB J. 24, 2631-2640 (2010).
52. Mediero, A., Perez-Aso, M. & Cronstein, B. N. Activation of adenosine A2A receptor reduces osteoclast formation via PKA- and ERK1/2-mediated suppression of NFkappaB nuclear translocation. Br. J. Pharmacol. 169, 1372-1388 (2013).
53. Nauseef, W. M. Biological roles for the NOX family NADPH oxidases. J. Biol. Chem. 283, 16961-16965 (2008).
54. Lee, I. T. & Yang, C. M. Role of NADPH oxidase/ROS in pro-inflammatory mediators-induced airway and pulmonary diseases. Biochem. Pharmacol. 84, 581-590 (2012).
55. Tang, X. N., Cairns, B., Kim, J. Y. & Yenari, M. A. NADPH oxidase in stroke and cerebrovascular disease. Neurol. Res. 34, 338-345 (2012).
56. Holland, S. M. Chronic granulomatous disease. Hematol. Oncol. Clin. North Am. 27, 89-99 viii (2013).
57. Bai, A. et al. All-trans retinoic acid down-regulates inflammatory responses by shifting the Treg/Th17 profile in human ulcerative and murine colitis. J. Leukoc. Biol. 86, 959-969 (2009).
58. Bai, A., Lu, N., Guo, Y., Chen, J. & Liu, Z. Modulation of inflammatory response via alpha2-adrenoceptor blockade in acute murine colitis. Clin. Exp. Immunol. 156, 353-362 (2009).
59. Bai, A. et al. Novel anti-inflammatory action of 5-aminoimidazole-4- carboxamide ribonucleoside with protective effect in dextran sulfate sodiuminduced acute and chronic colitis. J. Pharmacol. Exp. Ther. 333, 717-725 (2010).
60. Bian, S. et al. P2X7 integrates PI3K/AKT and AMPK-PRAS40-mTOR signaling pathways to mediate tumor cell death. PloS ONE 8, e60184 (2013).
61. Astier, A. L. et al. RNA interference screen in primary human T cells reveals FLT3 as a modulator of IL-10 levels. J. Immunol. 184, 685-693 (2010).
62. Sun, X. et al. CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 139, 1030-1040 (2010).